Takashi Masui

Takashi Masui

Auto-generated profile, based on publicly available information

Takashi Masui

Department of Otolaryngology-Head and Neck Surgery, Kindai University Nara Hospital, Ikoma, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1993 in Teratogenesis, Carcinogenesis, and Mutagenesis
Verified
Journal Article
Closed access
PDF file
TMT. Masui
T. Masui
AMA. M. Mann
A. M. Mann
CBC. D. Borgeson
C. D. Borgeson
EGE. M. Garland
E. M. Garland
Tomonori OkamuraTomonori Okamura
Tomonori Okamura
SCS. M. Cohen
S. M. Cohen

1 January 2020 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
NKNaoki Kakuta
Naoki Kakuta
RNRyuichi Nakano
Ryuichi Nakano
ANAkiyo Nakano
Akiyo Nakano
YSYuki Suzuki
Yuki Suzuki
ATAyako Tanouchi
Ayako Tanouchi
HYHisakazu Yano
Hisakazu Yano
Kakuta N, et al. Ann Lab Med. 2020 Jan;40(1):27-32. https://doi.org/10.3343/alm.2020.40.1.27

15 March 2025 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
TMTakashi Masui
Takashi Masui
KYKatsunari Yane
Katsunari Yane
IOIchiro Ota
Ichiro Ota
Kenichi KakudoKenichi Kakudo
Kenichi Kakudo
TWTomoko Wakasa
Tomoko Wakasa
TKTadashi Kitahara
Tadashi Kitahara
Background: We report a new risk stratification of invasive stage papillary thyroid carcinomas (PTCs) by combining invasive status, using extrathyroid invasion (Ex) status, and tumor growth speed using the Ki-67 labeling index (LI). Methods: We examined tumor recurrence in 167 patients with PTC who were surgically treated at the Kindai University Nara Hospital between 2010 and 2022. The patients were classified according to the degree of invasion [negative (Ex0) or positive (Ex1, Ex2, and Ex3)] and tumor growth speed expressed with Ki-67 LI, as low (5%). This study confirmed previous findings that the disease-free survival (DFS) rate in PTCs significantly differed between patients with a high and low Ki-67 index. Results: When combining Ex status (negative or positive) and Ki-67 proliferation status (low or high), the DFS rate of invasion in the negative, low Ki-67 LI group was only 1.1%, while that of invasion in the positive, high Ki-67 LI was 44.1%. This study reports for the first time that recurrence risks can be stratified accurately when combining carcinoma’s essential two features of extrathyroid invasion status and tumor growth speed. Conclusions: We believe the evidence for low tumor recurrence risk may contribute to use of more conservative treatment options for invasive-stage PTCs and help alleviate patient anxiety about tumor recurrence and death.